RecruitingPhase 1NCT05195710

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases


Sponsor

M.D. Anderson Cancer Center

Enrollment

50 participants

Start Date

Nov 16, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a liver treatment called Y-90 radioembolization (tiny radioactive beads injected into liver blood vessels) to help shrink colorectal cancer that has spread to the liver and to grow enough healthy liver tissue so that surgery becomes possible. **You may be eligible if...** - You have colorectal cancer that has spread to the liver but not elsewhere - Your liver tumors are currently too large to remove safely, but surgery might be possible after treatment - You have received at least 4 cycles (or 2 months) of chemotherapy - You are in good enough health to undergo surgery **You may NOT be eligible if...** - Your cancer has spread beyond the liver - You have severe liver disease or inadequate liver function - You are not a candidate for surgery even after treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGYttrium-90 (Y-90) resin microspheres

Given by scan


Locations(1)

M D Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05195710


Related Trials